Kala Pharmaceuticals

OverviewSuggest Edit

Kala Pharmaceuticals, Inc. (Kala) is a clinical-stage pharmaceutical company focused on innovative nanoparticle-based treatments for ocular diseases affecting both front and back of the eye. Kala leverages its proprietary mucus-penetrating particle (MPP) technology to develop topical ophthalmic formulations with enhanced delivery into ocular tissue by facilitating penetration through the tear film mucus. Kala’s lead program, a shelf-stable MPP nanosuspension of an ophthalmic corticosteroid, is in clinical trials for the treatment of post-surgical ocular inflammation, dry eye disease, and meibomian gland disease.

Kala is also advancing its novel, small molecule receptor tyrosine kinase inhibitor (RTKi) program as a potential topical treatment of wet age-related macular degeneration (AMD). Beyond ophthalmology, Kala’s MPP technology has potential applications in women’s reproductive health, respiratory and gastrointestinal diseases, and other indications.

TypePublic
Founded2009
HQWatertown, US
Websitekalarx.com

Latest Updates

Employees (est.) (Feb 2019)37(+48%)
Revenue (FY, 2015)$45 K
Share Price (Sept 2020)$8.9 (-9%)
Cybersecurity ratingBMore

Key People/Management at Kala Pharmaceuticals

Justin Hanes

Justin Hanes

Co-Founder and Director
Mark Iwicki

Mark Iwicki

Chairman and Chief Executive Officer
Kim Brazzell

Kim Brazzell

Chief Medical Officer
Howard B. Rosen

Howard B. Rosen

Director
Charlie McDermott

Charlie McDermott

Executive Vice President of Business Development
Hongming Chen

Hongming Chen

Chief Scientific Officer
Show more

Kala Pharmaceuticals Office Locations

Kala Pharmaceuticals has offices in Watertown and Waltham
Watertown, US (HQ)
490 Arsenal Way #120Watertown
Waltham, US
100 Beaver St #201
Show all (2)

Kala Pharmaceuticals Financials and Metrics

Kala Pharmaceuticals Revenue

Kala Pharmaceuticals's revenue was reported to be $45 k in FY, 2015
USD

Net income (FY, 2016)

(33.2m)

EBIT (FY, 2016)

(32.7m)

Market capitalization (21-Sept-2020)

501.2m

Closing stock price (21-Sept-2020)

8.9

Cash (31-Dec-2016)

42.5m
Kala Pharmaceuticals's current market capitalization is $501.2 m.
USDFY, 2015FY, 2016

Revenue

45.0k

General and administrative expense

4.6m7.6m

R&D expense

11.4m25.0m

Operating expense total

16.0m32.7m
USDFY, 2015FY, 2016

Cash

5.8m42.5m

Current Assets

7.6m45.6m

PP&E

738.0k594.0k

Total Assets

8.4m46.3m
USDFY, 2015FY, 2016

Net Income

(16.7m)(33.2m)

Depreciation and Amortization

330.0k297.0k

Accounts Payable

911.0(343.0)

Cash From Operating Activities

(15.1m)(27.3m)
Show all financial metrics

Kala Pharmaceuticals Operating Metrics

FY, 2016

Patent Applications

101

Patents (Foreign)

2

Patents (US)

6
Show all operating metrics

Kala Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

Kala Pharmaceuticals Online and Social Media Presence

Embed Graph

Kala Pharmaceuticals News and Updates

Kala Pharmaceuticals Blogs

Kala Pharmaceuticals Announces Virtual-Only Format for 2020 Annual Meeting of Stockholders

WATERTOWN, Mass. --(BUSINESS WIRE)--Jun. 10, 2020-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that its 2020 Annual Meeting of Stockholders

Kala Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

WATERTOWN, Mass. --(BUSINESS WIRE)--May 27, 2020-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the Jefferies Virtual

Kala Pharmaceuticals Announces FDA Acceptance of New Drug Application for EYSUVIS™ for Dry Eye Disease

Kala Pharmaceuticals Announces FDA Acceptance of New Drug Application for EYSUVIS™ for Dry Eye Disease Content Import Tue, 05/26/2020 - 08:00 Kala Pharmaceuticals Announces FDA Acceptance of New Drug Application for EYSUVIS™ for Dry Eye Disease May 26, 2020 at 8:00 AM EDT …

Kala Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update

-- Announced Positive Results from STRIDE 3 Clinical Trial of EYSUVIS in March 2020 , Demonstrating Statistically Significant Results for Primary and Key Secondary Endpoints -- -- EYSUVIS TM NDA Resubmitted on April 30 th ; Potential Approval and Launch Before Year-End -- -- Raised $146.9 Million

Kala Pharmaceuticals to Present at BofA Securities 2020 Health Care Conference

WATERTOWN, Mass. --(BUSINESS WIRE)--May 6, 2020-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the virtual BofA Securities

Kala Pharmaceuticals Resubmits New Drug Application for EYSUVIS™ for Dry Eye Disease

WATERTOWN, Mass. --(BUSINESS WIRE)--May 4, 2020-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has resubmitted its New Drug Application (NDA)
Show more

Kala Pharmaceuticals Frequently Asked Questions

  • When was Kala Pharmaceuticals founded?

    Kala Pharmaceuticals was founded in 2009.

  • Who are Kala Pharmaceuticals key executives?

    Kala Pharmaceuticals's key executives are Justin Hanes, Mark Iwicki and Kim Brazzell.

  • How many employees does Kala Pharmaceuticals have?

    Kala Pharmaceuticals has 37 employees.

  • Who are Kala Pharmaceuticals competitors?

    Competitors of Kala Pharmaceuticals include Biogen, MyoKardia and Otonomy.

  • Where is Kala Pharmaceuticals headquarters?

    Kala Pharmaceuticals headquarters is located at 490 Arsenal Way #120Watertown, Watertown.

  • Where are Kala Pharmaceuticals offices?

    Kala Pharmaceuticals has offices in Watertown and Waltham.

  • How many offices does Kala Pharmaceuticals have?

    Kala Pharmaceuticals has 2 offices.